Pro Medicus Limited (ASX:PME)
Australia · Delayed Price · Currency is AUD | Market Cap | 19.99B -27.4% |
| Revenue (ttm) | 261.69M +22.9% |
| Net Income | 265.34M +130.3% |
| EPS | 2.54 +130.3% |
| Shares Out | 104.47M |
| PE Ratio | 75.45 |
| Forward PE | 102.97 |
| Dividend | 0.74 (0.39%) |
| Ex-Dividend Date | Sep 7, 2026 |
| Volume | 137,472 |
| Open | 192.16 |
| Previous Close | 193.27 |
| Day's Range | 186.19 - 195.51 |
| 52-Week Range | 107.75 - 272.85 |
| Beta | 0.64 |
| Analysts | Buy |
| Price Target | 202.61 (+5.9%) |
| Est. Earnings | Nov 12, 2026 |
About Pro Medicus
Pro Medicus Limited, a healthcare informatics company, provides medical imaging software and services to hospitals, imaging centers, and health care groups in Australia, Europe, and North America. The company offers Visage RIS, an enterprise-class radiology information system for patient registration, billing, scheduling, typing, HL7 integration, financial reporting, picture archive and communication system (PACS) integration, digital dictation, and voice recognition integration; and Visage RIS/PACS, a solution for imaging needs of organization... [Read more]
Financial Performance
In fiscal year 2026, Pro Medicus's revenue was 261.69 million, an increase of 22.87% compared to the previous year's 212.98 million. Earnings were 265.34 million, an increase of 130.30%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for PME stock is "Buy." The 12-month stock price target is $202.61, which is an increase of 5.90% from the latest price.
News
Pro Medicus Shares Hit Near Two-Month High as New US Hospital Contracts Spark Broker Upgrades and 4.7% Jump
Pro Medicus shares rose 4.7% to A$193.42 after new U.S. hospital contracts and improved broker sentiment extended the medical imaging software company's recent rally.
Pro Medicus Secures A$43 Million, Seven-Year Deal With Virtua Health
(RTTNews) - Pro Medicus Ltd. (PME.AX, PMCUF), a healthcare informatics company, announced that its wholly owned U.S. subsidiary, Visage Imaging, Inc., has signed a seven-year, A$43 million contract wi...
Pro Medicus Earnings Call Transcript: H2 2026
Record revenue and profit growth driven by strong U.S. performance, major contract wins, and product innovation. Margins improved, cash reserves increased, and a robust pipeline supports a positive FY 2027 outlook. Recurring revenue and cloud adoption remain key strengths.
Pro Medicus Earnings release: H2 2026
Pro Medicus released its H2 2026 earnings on August 17, 2026, summarizing the period's financial results.
Pro Medicus Annual report: H2 2026
Pro Medicus has published its H2 2026 annual report on August 17, 2026.
Pro Medicus Slides: H2 2026
Pro Medicus has posted slides in relation to its H2 2026 quarterly earnings report, which was published on August 17, 2026.
Pro Medicus downgraded to Hold from Buy at Jefferies
Jefferies assumed coverage of Pro Medicus (PMCUF) and downgraded it to Hold from Buy with a price target of A$192.60, up from A$147. While the analyst does not believe outside…
Pro Medicus upgraded to Buy from Hold at Jefferies
Jefferies analyst Wei Sim upgraded Pro Medicus (PMCUF) to Buy from Hold with a A$155 price target With over 90% recurring revenue and a capital-light model, the firm remains confident…
Pro Medicus Earnings Call Transcript: H1 2026
Revenue and EBIT grew over 28% year-over-year, driven by record contract wins and expanding cloud-native, full-stack solutions. Major deals in cardiology and pathology, a robust pipeline, and strong margin performance set the stage for accelerated growth in the second half and beyond.
Pro Medicus Quarterly report: H1 2026
Pro Medicus has published its H1 2026 quarterly earnings report on February 11, 2026.
Pro Medicus Slides: H1 2026
Pro Medicus has posted slides in relation to its H1 2026 quarterly earnings report, which was published on February 11, 2026.
Pro Medicus Earnings release: H1 2026
Pro Medicus released its H1 2026 earnings on February 11, 2026, summarizing the period's financial results.
Pro Medicus Transcript: AGM 2025
The AGM highlighted record financial results, a strong contract pipeline, and increased dividends. Strategic investments in AI, cloud, and new products underpin growth, while the board prepares for expansion and governance enhancements. All resolutions passed with strong shareholder support.
Pro Medicus Slides: FY 2025
Pro Medicus has posted slides in relation to its FY 2025 quarterly earnings report, which was published on November 23, 2025.
Pro Medicus Earnings Call Transcript: H2 2025
Record FY25 with revenue up 32%, profit after tax up 40%, and margins at 74%. Secured $520M in new contracts, expanded into cardiology and digital pathology, and maintained 100% renewal rate. Cloud and AI offerings drive competitive advantage.
Pro Medicus Annual report: H2 2025
Pro Medicus has published its H2 2025 annual report on August 13, 2025.
Pro Medicus Slides: H2 2025
Pro Medicus has posted slides in relation to its H2 2025 quarterly earnings report, which was published on August 13, 2025.
Pro Medicus Earnings release: H2 2025
Pro Medicus released its H2 2025 earnings on August 13, 2025, summarizing the period's financial results.
Pro Medicus Earnings Call Transcript: H1 2025
Record first-half results with revenue up 31.1% and profit after tax up 42.7% year-over-year. Major new contracts and renewals, strong pipeline replenishment, and expanding margins position the company for accelerated growth in the second half and FY2026.
Pro Medicus Quarterly report: H1 2025
Pro Medicus has published its H1 2025 quarterly earnings report on February 12, 2025.
Pro Medicus Slides: H1 2025
Pro Medicus has posted slides in relation to its H1 2025 quarterly earnings report, which was published on February 12, 2025.
Pro Medicus Earnings release: H1 2025
Pro Medicus released its H1 2025 earnings on February 12, 2025, summarizing the period's financial results.
Pro Medicus initiated with an Overweight at Morgan Stanley
Morgan Stanley initiated coverage of Pro Medicus (PMCUF) with an Overweight rating and A$300 price target PME Visage 7 software “creates significant value for its customers, underpinning our confidenc...
Pro Medicus Shares Gain on Upbeat Outlook
Shares of the ASX-listed Pro Medicus Limited ($AU:PME) extended their rally today, driven by the company’s upbeat outlook for FY25. In its AGM (annual general meeting) presentation for FY24, the…
Pro Medicus Transcript: AGM 2024
Record financial results, major contract wins, and increased dividends highlighted a strong year. Strategic focus remains on the U.S. market, AI, and cloud innovation, with robust governance and high shareholder support for all resolutions.